Table S2 from Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

Authors:

Abstract
Table S2 shows abscopal effects in a single non-injected lesion by percent change from baseline, as well as the location of the lesion.